AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05340010 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Human Chorionic Gonadotrophin Intramuscular injection 10.000 IU
Description: From the 12th to 13th day of the cycle when endometrium reached the optimal thickness ≥8 mm, group 1 (hCG) will receive 10.000 IU hCG intramuscular injection in the morning then vaginal suppository progesterone 400 mg twice a day will be started in the afternoon
Study NCT00440297 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Comparator: modified process hepatitis B vaccine
Description: Modified process hepatitis B vaccine 40 ug/1.0 mL injection in a 4 dose regimen at months 0, 1, 6, and 8. Duration of treatment is 9 months.
Study NCT00440297 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Comparator: ENGERIX-B™
Description: ENGERIX-B™ two 20 ug/1.0 mL injections in a 4 dose regimen at months 0, 1, 6, and 8. Duration of treatment is 9 months.
Study NCT03012178 — intervention group
Intervention type: PROCEDURE
Intervention: Mitral valve surgery
Description: ACC/AHA guideline directed mitral valve repair or replacement
Study NCT04558905 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Face-to-face medical visits
Description: Face-to-face medical visits
Study NCT04558905 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Alternating face-to-face medical visits and video medical consultations
Description: Alternating face-to-face medical visits and video medical consultations
Study NCT05068609 — intervention group
Intervention type: BIOLOGICAL
Intervention: Nivolumab
Description: Participants in this study are being treated with nivolumab for SCCHN
Study NCT02061852 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Simeox
Study NCT02061852 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Simeox
Study NCT02877186 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: commercially-available diet soda
Description: Subjects are asked to consume diet soda three times daily for one week.
Study NCT02877186 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: carbonated water (control)
Description: Subjects are asked to consume carbonated water three times daily for one week.
Study NCT02005705 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Outpatient Management of Low-risk Patients
Description: * Labs will be obtained within 2-3 days of discharge from ED~* Clinic visit will be scheduled within 3 days of discharge from ED~* EGD will be scheduled within 7 days of discharge from ED~* Phone follow-up at day 7 and 30
Study NCT02005705 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Inpatient Management of Low-risk Patients
Description: * Labs will be obtained on day of discharge or day 2-3~* EGD will be performed in the hospital~* Phone follow-up at day 7 and 30
Study NCT01762085 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: nerve decompression
Description: surgical decompression involves surgical division or incision of perineural fibrous or fibro-osseous tunnel tissues which pinch, choke, compress or sharply deviate nerve trunks.
Study NCT02061852 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Physiotherapy
Study NCT02061852 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Physiotherapy
Study NCT00783484 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-03716539
Description: PF-03716539 50 mg oral solution, single dose
Study NCT00783484 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo for 50 mg, 100 mg and 200 mg of PF-03716539 (single dose)
Study NCT00783484 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam
Description: Midazolam 1 mg IV, single dose
Study NCT00783484 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam + PF-03716539 (100 mg)
Description: Midazolam 1 mg IV, single dose plus PF-03716539 100 mg oral solution, single dose
Study NCT00783484 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam + PF-03716539 (50 mg)
Description: Midazolam 1 mg IV, single dose plus PF-03716539 50 mg oral solution, single dose
Study NCT00783484 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Darunavir
Description: Darunavir 600 mg tablet twice daily for 9 days (Days 1-9)
Study NCT00783484 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Darunavir + PF-03716539
Description: Darunavir 600 mg tablet, single dose plus PF-03716539 50 mg oral solution, single dose (Day 10)
Study NCT02758457 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: dental crowns
Study NCT02758457 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: dental crowns
Study NCT00756938 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: losartan potassium
Description: losartan potassium, dry powder, to be suspended in liquid and given orally, once daily; doses will start at 0.1 mg/kg, 0.3 mg/kg, and 0.7 mg/kg, respectively, in the three study arms and can be escalated up to 1.4 mg/kg (maximum dose 100 mg) until target blood pressure is reached.
Study NCT02771522 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Calcivis System
Description: Following de-bond, and identification of active post-orthodontic white spot lesions at baseline with the Calcivis System, each active tooth will be again be imaged at 2, 4, 8 and 12 weeks. Both black \& white and luminescent images images of the teeth are taken. The images of each tooth are overlaid and a resulting demineralization map of the tooth produced, indicating areas of elevated bioluminescence corresponding to free calcium ions on the surface of the tooth (active caries)
Study NCT00441545 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fosrenol (Lanthanum Carbonate)
Description: The starting dose is a total daily dose of 2250mg of Fosrenol (Lanthanum carbonate) to a maximum dose of 3000mg daily. Chewable tablets will be administered orally with meals in 750mg and 1000mg strength tablets.
Study NCT00441545 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sevelamer hydrochloride
Description: The starting dose is a total daily dose of 4800mg of sevelamer hydrochloride up to a maximum of 6400 mg daily. Sevelamer hydrochloride 800mg tablets, administered orally with meals.
Study NCT00598299 — intervention group
Intervention type: PROCEDURE
Intervention: venous puncture
Description: venous puncture
Study NCT00598299 — intervention group
Intervention type: OTHER
Intervention: obtain serum from perripheral blood or cord blood
Description: obtain serum from perripheral blood or cord blood
Study NCT03437551 — intervention group
Intervention type: OTHER
Intervention: cross-sectional observation
Description: cross-sectional ophthalmic examination
Study NCT00783484 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Maraviroc
Description: Maraviroc 150 mg tablet once daily for 6 days (Days 1-6)
Study NCT02213874 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Questionnaire
Description: A questionnaire will be administered during the early stages of prenatal care \& again during the postpartum period. The initial questionnaire will assess trust in the health care system, locus of control, religiosity, health literacy \& collect information about demographics, contraceptive \& reproductive history, future pregnancy intentions, \& baseline knowledge about contraception. The postpartum questionnaire will repeat questions about future pregnancy \& contraception intentions, trust in the health care system, knowledge of contraception and collect new information about characteristics of antenatal contraceptive counseling received including whether a provider recommended a specific method of contraception, the amount of counseling received, \& the type of counseling received.
Study NCT01717469 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Left ventricular pacing through coronary sinus tributaries (Attain StarFix)
Description: Left ventricular pacing in patients with bradycardia
Study NCT01717469 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Right ventricular pacing (Medtronic)
Description: Conventional right ventricular pacing in patients with bradycardia.
Study NCT03078465 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ticagrelor
Description: Daily administration of ticagrelor 180mg for 12 months
Study NCT03078465 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clopidogrel
Description: Daily administration of clopidogrel 150mg for 12 months
Study NCT03671928 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: additional blood tube
Description: sampling of an additional tube at the usual blood test to determine the glicentin level
Study NCT03671928 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: additional blood sample
Description: for le group control, another blood sample is taken outside the usual care.
Study NCT00828282 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Simvastatin
Description: Treatment will be administered on an outpatient basis. Subjects will be given 7.5 mg/kg twice daily of Simvastatin for 7 days on a 21-day cycle with a goal of 6 cycles.
Study NCT03539445 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Butylphthalide
Description: This group will receive a 3-month regimen of Butylphthalide and Sodium Chloride Injection 100ml twice/day in the initial 14 days and Butylphthalide Soft Capsules 0.2g triple/day for the rest Day 15 to Day 90.
Study NCT03539445 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Butylphthalide Placebo
Description: This group will receive a 3-month regimen of Butylphthalide Placebo Injection 100ml twice/day in the initial 14 days and Butylphthalide Placebo Soft Capsules 0.2g triple/day for the rest Day 15 to Day 90.
Study NCT04276207 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY900014
Description: Administered by CSII
Study NCT04276207 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin Lispro
Description: Administered by CSII
Study NCT04297215 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: DermaCura® Chitosan based antimicrobial therapeutic clothing
Description: DermaCura® antimicrobial therapeutic clothing (D\&M) consists of 98% TENCEL® and 2% elastane. 1% chitosan has been added to TENCEL®~The therapeutic clothing is to be worn at night during the 12-month intervention period and if needed during the day. Usual care including application of emollients, corticosteroid ointments or creams only if needed and/or antihistamines is continued, with standardized steroid ointments and treatment regimens for comparability purposes.
Study NCT04297215 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Binamed® silver based antimicrobial therapeutic clothing
Description: The Binamed® antimicrobial therapeutic clothing (BAP Medical) consists of micro-modal, lycra and woven silver filaments as antibacterial agent.~The therapeutic clothing is to be worn at night during the 12-month intervention period and if needed during the day. Usual care including application of emollients, corticosteroid ointments or creams only if needed and/or antihistamines is continued, with standardized steroid ointments and treatment regimens for comparability purposes.
Study NCT04297215 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Binamed® therapeutic clothing without antimicrobial agents
Description: The Binamed® therapeutic clothing without antimicriobial agents (BAP Medical) is therapeutic clothing made of micro-modal and lycra. Micro-madal is a semi-synthetic wood cellulose fiber. This fiber has a high strength hand elasticity, a high moisture-permeability and feels soft. Lycra ensures an optimal fit on the skin.~The therapeutic clothing is to be worn at night during the 12-month intervention period and if needed during the day. Usual care including application of emollients, corticosteroid ointments or creams only if needed and/or antihistamines is continued, with standardized steroid ointments and treatment regimens for comparability purposes.
Study NCT03642145 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Deflazacort
Description: Deflazacort tablets will be administered as per schedule and dose specified in respective arms.
Study NCT01679041 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alemtuzumab
Description: Alemtuzumab 10 mg given IV on day 1 of the 5 day conditional regimen
Study NCT01679041 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Fludarabine 25mg/m2 daily given IV on days 1-5 of the 5 day conditioning regimen
Study NCT01679041 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Cyclophosphamide is given 3 gm/m2 for mobilization, and then repeated during 5 day conditioning regimen w/ doses of 50mg/kg/day on days 1-4
Study NCT04123158 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Ultrasound
Description: Intervention: Diagnostic Test Ultrasound Ultrasound investigating the following characteristics: Maximum size of the lesion ≥ 8cm; Largest diameter rapid growth (Growth >30% per year); Irregular margins of the lesion; Presence of irregular cystic areas; Absence of acoustic shadow; Color Score 4; Cooked aspect; \]
Study NCT04123158 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: MRI
Description: Diagnostic Test: MRI; MRI investigating the following carachteristics:~TARGET LESION Maximum diameter; Borders; Signal intensity on T2WI; Heterogeneity on T2WI; Cystic alteration(s); Cystic alteration(s) borders; Hemorrhage; T2 dark area(s); Flow voids; Signal intensity on DWI(b-1000); ADC value; ≥ 1,23 Signal intensity on contrasted images Intensity \[relative to myometrium\] (Hyper- / Hypo- / Iso- intense) Heterogeneity (Homogeneous / Heterogeneous) Unenhanced area(s) Presence (Present / Absent) Location (Central / None or non-central) 1 Tumour - myometrium contrast ratio on T2WI \[SItumour - SImyometrium / SImyometrium\]
Study NCT01262976 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GSK's investigational vaccine 692342
Description: Intramuscular, 2 doses
Study NCT01262976 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Physiological saline
Description: Intramuscular, 2 doses
Study NCT02769728 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EndoBarrier
Description: implantation of a duodeno-jejunal bypass liner for weight reduction in obese subjects with type 2 diabetes mellitus
Study NCT00266253 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GK Activator (2)
Description: Escalating doses, po bid or qd for 12 weeks.
Study NCT00266253 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: As prescribed, for 12 weeks
Study NCT00783484 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Maraviroc +PF-03716539
Description: Maraviroc 150 mg tablet, single dose plus PF-03716539 100 mg oral solution, single dose (Day 7)
Study NCT00783484 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Maraviroc
Description: Maraviroc 225 mg tablet once daily for 6 days (Days 1-6)
Study NCT00266253 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin
Description: As prescribed, for 12 weeks
Study NCT03489798 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: 6 misoprostol
Description: Up to 6 doses of 25ug of misoprostol applied every 6 hours. End point is cervical Bishop score > 6.
Study NCT03489798 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: 3 misoprostol
Description: Up to 3 doses of 25ug of misoprostol applied every 6 hours. End point is cervical Bishop score > 6.
Study NCT01726088 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Modafinil
Description: we will compare the effect of modafinil and matching placebo on clinical and objective measures detailed above.
Study NCT01726088 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Modafinil
Description: we will compare the effect of modafinil and matching placebo on clinical and objective measures detailed above.
Study NCT03624946 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Zika Virus Immune Globulin (ZIKV-IG)
Description: Zika Virus Immune Globulin (ZIKV-IG) is a human immune globulin preparation containing neutralizing antibodies to Zika virus.
Study NCT03624946 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo is a normal saline solution (0.9% sodium chloride).
Study NCT03838224 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: dry needling
Description: Participants allocated in this group will receive a single session of dry needling of the obliquus capitis inferior. Prior to the intervention, participants will receive information about the procedure and will be free to withdraw. The needle was shown to the participant before the intervention. Participants will be requested to lie in prone on the plinth. Participants' skin will be sterilized with antiseptic spray for the skin. The therapist will clean his hands and use sterilized gloves. The needle will be moved up and down within the muscle, using a fast-in and fast-out technique. Needle insertions will be repeated 12 times.
Study NCT03838224 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham needling
Description: Sham needling has shown to be a valid control method in dry needling research. The procedure in the sham group will be the same as the experimental group to guarantee the participants' blinding. Prior to the intervention, participants will receive information about the procedure and will be free to withdraw. The sham needle (same appearance/material as the true needle) was shown to the participant before the intervention to guarantee the blinding.
Study NCT04853628 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Alerta Alcohol
Description: The intervention consists of preventive messages about the benefits of not consuming alcohol, reducing the positive attitudes and encouraging the negative attitudes towards alcohol drinking and BD, as well as social influence and self-efficacy, by personalized feedback. Skills and action plans are encouraged to help the student to reject BD. This information is presented through different tailored text messages. Moreover, several gamification strategies are used (i.e. offering a challenge, giving different stories and the use of avatars in these stories that take place in three different scenarios: at home, at celebrations and in public places).
Study NCT04853628 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Alerta Alcohol 2.0
Description: The intervention consists of preventive messages about the benefits of not consuming alcohol, reducing the positive attitudes and encouraging the negative attitudes towards alcohol drinking and BD, as well as social influence and self-efficacy, by personalized feedback. Skills and action plans are encouraged to help the student to reject BD. This information is presented through different animated videos. Moreover, new gamification strategies are added (i.e. giving rewards and allocating points that can be accumulated and shown in a progress ranking) to those already used in Alerta Alcohol.
Study NCT04126655 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Arfolitixorin
Description: Per operative administration of 5-FU with Arfolitixorin or Calciumfolinate
Study NCT04126655 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Arfolitixorin
Description: Per operative administration of 5-FU with Arfolitixorin or Calciumfolinate
Study NCT03711604 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tenalisib
Description: BID Orally
Study NCT02482155 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibuprofen
Description: ibuprofen 400 mg single dose oral solution
Study NCT00448708 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Vascular Wrap Paclitaxel-Eluting Mesh
Description: 0.9 µg/mm\^2 paclitaxel
Study NCT00448708 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Lifespan® ePTFE Vascular Graft
Description: vascular graft
Study NCT00448708 — intervention group
Intervention type: DEVICE
Group type: NO_INTERVENTION
Intervention: Lifespan® ePTFE Vascular Graft
Description: vascular graft
Study NCT00928421 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Polidocanol Endovenous Microfoam 0.125%
Description: Polidocanol Endovenous Microfoam 0.125%, single dose
Study NCT02198248 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rituximab
Description: Patients will be administered rituximab (375mg/m2/w x4 infusions) for reducing glucocorticoid dose in remission induction phase.
Study NCT02198248 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Patients will be administered rituximab (375mg/m2/w x4 infusions) for reducing glucocorticoid dose in remission induction phase.
Study NCT03366805 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pain Management Patient Education Video
Description: Patient education video that were created in-house specifically for this project.
Study NCT03366805 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Wound Care Patient Education Video
Description: Patient education video that were created in-house specifically for this project.
Study NCT02198248 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glucocorticoids
Description: Low-dose group commenced 0.5mg/kg/day, then taper and stop within 6 months following pre-defined schedule.~High-dose group commenced 1.0mg/kg/day, then taper to 10mg/day within 6 months following pre-defined schedule.
Study NCT02198248 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glucocorticoids
Description: Low-dose group commenced 0.5mg/kg/day, then taper and stop within 6 months following pre-defined schedule.~High-dose group commenced 1.0mg/kg/day, then taper to 10mg/day within 6 months following pre-defined schedule.